ArticleTranslational cancer research2025
Immune checkpoint inhibitors plus paclitaxel-based chemotherapy
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For unresectable or metastatic gastric/gastroesophageal junction cancer (G/GEJC), immune checkpoint inhibitors (ICIs) plus platinum-based doublet chemotherapy [FOLFOX (leucovorin, fluorouracil, and oxaliplatin) and XELOX (capecitabine and oxaliplatin)] are currently recommended as the standard first-line treatment. Research indicates that ICIs combined with paclitaxel have a synergistic effect, but the evidence is insufficient. This multicenter, retrospective study aimed to compare the efficacy and tolerability of ICIs [mainly anti-programmed cell death-1 (anti-PD-1) antibodies] plus a paclitaxel-based chemotherapy regimen (ICIs plus PTX) Methods: This research involved 123 patients with advanced G/GEJC at three institutions in China from August 2019 to June 2022. The ICIs plus PTX group included 58 patients, whereas the ICIs plus OXA group included 65 patients. We compared the efficacy and safety of two treatment regimens. Results: Fifty-eight patients (47.2%) received ICIs plus PTX, and 65 patients (52.8%) received ICIs plus OXA. The median progression-free survival (PFS) [8.07 Conclusions: In summary, ICIs plus PTX are as effective as ICIs plus OXA for treating advanced G/GEJC with manageable toxicity. The advantages of ICIs plus PTX in terms of adverse events (AEs) may support it as an alternative to ICIs plus OXA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.